| Prev Close | 47.26 |
| Open | 47.41 |
| Day Low/High | 47.36 / 47.84 |
| 52 Wk Low/High | 41.23 / 52.83 |
| Volume | 1.07M |
| Avg Volume | 1.31M |
Latest News
News Surrounds 3 Small Biotechs, With a Merger Claiming One
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
Gilead Sciences Teams With Novo Nordisk for Trials of Liver Disease Drugs
Gilead Sciences is partnering with Novo Nordisk to help combat liver disease.
Downgrades Are Important: Cramer's 'Mad Money' Recap (Monday 4/8/19)
Jim Cramer says these downgrades may be well-reasoned, but he wants to know if they're correct.
Ollie's Bargain Outlet, Novo Nordisk, Avnet: 'Mad Money' Lightning Round
Jim Cramer weighs in on Ollie's Bargain Outlet, Novo Nordisk, Avnet, Cabot Corp., Helmerich & Payne, Amarin, Golar LNG, Nio and more.
These 2 Biotech Stocks Seem Significantly Undervalued
I would add to them on any significant dips in the market.
Xultophy® Now Available In Canada To Support Improved Glycemic Control, An Issue Facing 50 Per Cent Of Canadians With Type 2 Diabetes
An estimated 3.1 million Canadians live with type 2 diabetes, half of whom do not achieve adequate blood sugar control 1,2,3 Once-daily Xultophy ® combines insulin degludec and liraglutide to help patients achieve blood glucose targets, with a...
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Stocks Mixed as Asia Gets China Trade Boost, Wall Street Rides Earnings Wave
Global stocks were mixed Wednesday, with stronger-than-expected trade data from China, as well as the expectation of further stimulus from Beijing, boosting shares in Asia while softer earnings in Europe held down gains for stocks on the Continent.
Exiting Eli Lilly Position
We are taking a win, closing our LLY position and minimizing risk just a few days before it reports second-quarter earnings.
Drug Pricing Turns to Insulin as Politicians, AMA and Docs Look to Pharma
Insulin has been around since 1921. But there is no generic drug and four companies control the market. Now politicians, the AMA and patient groups are looking for lower prices.
Novo Nordisk Stock Rises 4% Over 2 Sessions
Pharma firm's new diabetes drug showed positive test results.
Novo Nordisk Stock Pops Nearly 3% on Positive Diabetes-Drug Results
The Danish company's shares are enjoying their best day since May 2.
Eli Lilly's Trulicity Benefits From Growth of Diabetes Drugs
Senior vice president Enrique Conterno says the Type-2 diabetes treatment is part of the fast-growing glucagon-like peptide-1 receptor agonists.
Buying More Lilly
We are picking up LLY shares into weakness, below our basis in the process.
Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices
While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.
Eli Lilly Beats Estimates, but Shares Head Lower Amid Diabetes Concerns
BMO Capital Markets analyst Alex Arfaei says the fourth-quarter results show how dependent the drugmaker is on major diabetes assets 'and doesn't alleviate our concerns.'
Sanofi Announces Second Billion-Dollar Deal In a Week, and It May Not Be Done
A week after unveiling an $11.6-billion deal for Bioverativ, Sanofi said it was spending another $4.8 billion to acquire Belgian biotech firm Ablynx.
5G, Sanofi, Ablynx, Coincheck and Bruno Mars - 5 Things You Must Know
U.S. stock futures trade lower, Donald Trump's national security advisers look at building a 5G network, and France's Sanofi buys Belgian biotech Ablynx.
